Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 6—June 2019
Dispatch

Pertactin-Negative and Filamentous Hemagglutinin-Negative Bordetella pertussis, Australia, 2013–2017

Zheng Xu, Sophie Octavia, Laurence Don Wai Luu, Michael Payne, Verlaine Timms, Chin Yen Tay, Anthony D. Keil, Vitali Sintchenko, Nicole Guiso, and Ruiting LanComments to Author 
Author affiliations: University of New South Wales, Sydney, New South Wales, Australia (Z. Xu, S. Octavia, L.D.W. Luu, M. Payne, R. Lan); New South Wales Health Pathology and Westmead Hospital, Sydney (V. Timms, V. Sintchenko); The University of Sydney, Sydney (V. Timms, V. Sintchenko); University of Western Australia, Perth, Western Australia, Australia (C.Y. Tay); Perth Children’s Hospital, Perth (A.D. Keil); Institut Pasteur, Paris, France (N. Guiso)

Main Article

Figure 1

Pertussis trends and temporal changes of allele frequencies of vaccine antigens genes, Australia. A) Pertussis notifications in Australia, 1991–2017. Source: National Notifiable Diseases Surveillance System (http://www9.health.gov.au/cda/source/cda-index.cfm). Incidence is number of cases per 100,000 population. Reporting system was established in 1991. ACV was first introduced in Australia in 1997, and WCV was replaced with ACV in 1999. A large pertussis epidemic occurred during 2008–2012, and

Figure 1. Pertussis trends and temporal changes of allele frequencies of vaccine antigens genes, Australia. A) Pertussis notifications in Australia, 1991–2017. Source: National Notifiable Diseases Surveillance System (http://www9.health.gov.au/cda/source/cda-index.cfm). Incidence is number of cases per 100,000 population. Reporting system was established in 1991. ACV was first introduced in Australia in 1997, and WCV was replaced with ACV in 1999. A large pertussis epidemic occurred during 2008–2012, and another epidemic occurred during 2013–2017. B) Percentage of Bordetella pertussis isolates carrying ptxP3 allele in the 2 epidemic periods. C) Percentage of B. pertussis isolates carrying fim3A and fim3B allele in the 2 epidemic periods. D) Percentage of pertactin-expressing (Prn-positive) and pertactin-deficient (Prn-negative) B. pertussis isolates in the 2 epidemic periods. ACV, acellular vaccine; Prn, pertactin; WCV, whole-cell vaccine.

Main Article

Page created: May 20, 2019
Page updated: May 20, 2019
Page reviewed: May 20, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external